Development and Validation of a Circulating Tumor DNA Detection Technique in Patients With Ovarian Cancer
In a first step, the different available techniques will be evaluated for specificity and
sensibility using serial dilutions of cell lines with or without TP53 mutation.
The tumor DNA detection rate will be estimated from patient's blood with ovarian cancer.
The investigators will study 25 patients to obtain at least 15 patients bearing a TP53
mutation that could be characterized in the primitive tumor or metastasis. With those 15
patients, the investigators will determine the most sensitive technique and the best
Intervention Model: Single Group Assignment, Masking: Open Label
Assessment and development of circulating tumor DNA detection techniques
Quantification of circulating tumor DNA in blood samples. Results expressed in number of samples where circulating DNA is present.
LANTZ Olivier, MD
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)